RS Research
Phase 1Sagitta® targeted delivery platforms are discovered to improve therapeutic index across a spectrum of payloads, addressing one of oncology’s most persistent challenges: The efficacy-toxicity trade-off.
Founded
2016
Focus
Nanotechnology
About
Sagitta® targeted delivery platforms are discovered to improve therapeutic index across a spectrum of payloads, addressing one of oncology’s most persistent challenges: The efficacy-toxicity trade-off.
Company Info
TypePrivate
Founded2016
LocationZurich, Switzerland
StagePhase 1
Contact
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile